Mark Bodenrader - 09 Feb 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Title: Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer
Signature: /s/ Mark Bodenrader
Issuer symbol: N/A
Transactions as of: 09 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2022, 17:47:58 UTC
Next filing: 03 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Award	$0	+24,800		$0.000000	24,800	09 Feb 2022	Common Stock	24,800	$30.36	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter.

Remarks:

Title: Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer